Metabolic Health
Diabetes, the Liver, and the Quiet March of MASLD
A three-year cohort of type 2 diabetics tracked who silently progressed to liver fibrosis — and which routine lab markers offered the earliest warning.
Metabolic Health
Metabolic Health
Semaglutide in the Real World: New Cohorts, New Molecules, and the Limits of One-Size-Fits-All
As GLP-1 demand outpaces supply, fresh data from Karachi, a critical review of Asian-descent dosing, and an early trial of a novel Chinese molecule hint at a more personalized future for metabolic care.
Metabolic Health
After the Shot: What Actually Holds Weight Off When You Stop GLP-1s
A small real-world study suggests older, cheaper anti-obesity pills may help preserve much of the weight loss achieved on a year of GLP-1s — a practical lifeline as access and prices stay volatile.
Metabolic Health
GLP-1 Plus SGLT2: The Combination Case for Heart and Kidney Protection
A new meta-analysis confirms GLP-1 drugs protect the heart and kidneys. Real-world data suggests pairing them with SGLT2 inhibitors may compound the benefit — with caveats worth understanding.
Metabolic Health
Sitting Still: How Sedentary Time Became a Measurable Cancer Risk
A new wave of population-level research is moving the link between chair-time and cancer from slogan to statistics — and reframing movement as a quiet prevention lever for desk-bound lives.
Metabolic Health
What Happens When You Stop Your GLP-1: The Rebound Data
A real-world analysis tied to the dulaglutide shortage put concrete numbers on what happens to blood sugar in the three months after stopping. The picture is sobering — and worth bringing to your doctor.
Metabolic Health
Semaglutide's Second Act: Kidney Protection, Dosing Gaps, and the Next GLP-1s
The blockbuster weight-loss drug is being studied for far more than the scale. Here's what the newest research actually shows — and where the evidence still thins out.
Metabolic Health
GLP-1s in the Real World: What Adherence, Diet Coaching, and Combo Therapy Actually Look Like
Pooled real-world data on oral semaglutide, a fresh meta-analysis on combining GLP-1s with SGLT2 inhibitors, and dietitians' candid notes on what makes these protocols stick.